Browse the evidence

The study reported no substantial differences in the numbers of adverse events between the two groups.

Both dietary approaches appear to be safe with respect to adverse events.

GLP‐1RAs triggered more gastrointestinal adverse events than placebo, with no in‐between difference.

Clinicians should be aware of the gastrointestinal side effects associated with GLP-1RAs when prescribing these medications.

The prevalence of obesity among primary care patients increased from 39.2% in 2017 to 40.7% in 2019.

Healthcare providers should be aware of the rising obesity rates among their patients.

Aerobic exercise at 8 KKW did not induce weight change, and there was no significant change in any component of energy expenditure.

Lower intensity aerobic exercise may not be sufficient for weight loss or changes in energy expenditure.

Nonalcoholic fatty liver disease (NAFLD) affects more than 25% of adults worldwide.

Healthcare providers should be aware of the high prevalence of NAFLD in adult populations.

The majority of patients with NAFLD are unaware of their condition.

Awareness and screening for NAFLD should be prioritized in clinical practice.

From 2015 to 2019, the percentage of T2D patients treated with a GLP-1 RA increased from 3.2% to 10.7%.

Healthcare providers should be aware of the increasing adoption of GLP-1 RAs among T2D patients.

Lower rates of GLP-1 RA use were found among Asian, Black, and Hispanic patients with T2D.

Efforts should be made to address the disparities in GLP-1 RA access among racial and ethnic minorities.

There is no consensus definition of sarcopenia despite its evolving criteria.

Practitioners should be aware of the lack of consensus in defining sarcopenia when diagnosing and treating patients.

Overall relative search volume (RSV) for 'Ozempic' grew exponentially in the United States between March 2018 and February 2023.

Practitioners should be aware of the increasing public interest in Ozempic for weight loss.

Statistically significant differences in search popularity were found between 'Ozempic', 'Wegovy', and 'Mounjaro' from December 2021 to February 2023.

Surgeons should consider the varying popularity of these medications in their practice.

Fifty-two articles corresponding to five registries were included in the review.

This indicates a comprehensive analysis of existing data on weight loss maintenance.

In 2018, the mean global intake per person of unprocessed red meat was 51 g/day, with 17 countries having mean intakes of at least one serving (100 g) per day.

Practitioners should be aware of the significant global consumption of unprocessed red meat and target interventions accordingly.

Between 1990 and 2018, global intakes of unprocessed red meat, eggs, milk, processed meat, seafood, and cheese increased.

This trend indicates a growing consumption of certain animal-source foods, which may have implications for public health and nutrition policies.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to increase from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050.

Health systems should prepare for a significant increase in MASLD cases.

Cases of metabolic dysfunction-associated steatohepatitis (MASH) are expected to rise from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050.

Increased awareness and management strategies for MASH are needed.

Liver-related mortality is estimated to increase from 30,500 deaths (1.0% of all-cause deaths in adults) in 2020 to 95,300 deaths (2.4%) in 2050.

Strategies to reduce liver-related mortality must be prioritized.

There is a need for the development of highly efficacious and safe new agents for obesity treatment.

Healthcare providers should advocate for and support the development of new obesity treatments.

The FDA-approved label for resmetirom does not require liver biopsy to confirm the diagnosis of fibrotic MASH.

Clinicians can diagnose fibrotic MASH without the need for invasive liver biopsy, simplifying patient assessment.

The food industry in the United States generated nearly $900 billion in sales in 2000.

Understanding the scale of the food industry can inform marketing strategies.

Substituting water for SSBs was not associated with any outcome.

Practitioners should note that water substitution does not yield measurable benefits in this context.

Further research is needed to provide a clear differentiation between short and long inter-set rest intervals.

Researchers should conduct more studies to clarify the effects of different rest intervals.

There are significant research disparities in the data available on Asian American adults in risk prediction models, national surveillance surveys, and clinical trials.

More inclusive research efforts are needed to address health disparities in Asian American populations.

Nutritional biology can significantly contribute to the discovery of new molecular targets.

Practitioners should consider the role of nutrition in identifying new treatment targets.